Schneider, J. L., Lin, J. J. & Shaw, A. T. ALK-positive lung cancer: a moving target. Nat Cancer 4, 330–343 (2023). Article CAS PubMed PubMed Central Google Scholar Voena, C., Ambrogio, C., Iannelli, F. & Chiarle, R. ALK in cancer: from function to therapeutic targeting. Nat. Rev. Cancer 25, 359–378 (2025). Article CAS PubMed PubMed
Exploratory biomarker analyses were performed in 190 patients (nivolumab, 98 out of 229 (43%); placebo, 92 out of 232 (40%)) with evaluable paired tumour samples from screening and blood samples from ≥1 time point during the study for whole-exome sequencing (WES). These individuals constituted the biomarker-evaluable population. The most common reasons for exclusion were samples
